Email response from company...
Thank you for contacting the company regarding your investment in RxElite, Inc. The current name of the company is Landela Pharmaceutical but that is only a "doing business as" name for RxElite, Inc. In January 2009, RxElite sold RxElite Holdings, Inc (a wholly owned subsidiary) to Piramal Healthcare in India. To avoid market confusion we filed the dba certificate and changed the working name of RxElite, Inc. to Landela. It would require a shareholder vote and approval to change the name of the company in its entirety to Landela and at this time we are not anticipating asking for such a change. The stock symbol will remain RXEI and is traded on the pink sheets under RXEI.PK.
I am unaware that our website (www.landelapharma.com) mentions anything about future approvals of ANDAs. If it does, please point me to the specific page so that we can make appropriate corrections if necessary. We do have three approved ANDAs which are all currently not actively marketed. In the future this may change but we would need to find the appropriate outlet.
Our management team has focused on cutting expenses and refocusing the company. Our goal is to always protect shareholder value and we work diligently day to day to move the company forward. We would not be able at this time to comment on the stock price.
Best regards,
Earl E. Sullivan
Chief Executive Officer
Landela Pharmaceutical
776 East Riverside Drive
Suite 150
Eagle, Idaho 83616
Disclaimer: I'm not a paid promoter, broker nor an officer of a public company. My posts in certain stocks should not be construed as a recommendation to buy or sell such securities.
